Oculus Innovative Sciences Inc (NASDAQ:OCLS)

zjmoser (< 20) Submitted: 4/2/2013 3:39:56 AM : Start Price: $3.46 OCLS Score: +6.55

Growth prospects

import2udirect (< 20) Submitted: 4/24/2012 11:47:27 AM : Start Price: $6.97 OCLS Score: -65.37

down because the market is down long term could be a winner

Casew (< 20) Submitted: 2/25/2012 10:53:31 AM : Start Price: $9.17 OCLS Score: -80.15

When this company went public back in 2007, it's share price peaked at around $11. It has steadily gone down since then and now typically trades at a little over $1.

What's interesting about this is that it's revenue has actually grown from $94,000 in 2004 to $9,754,000 in 2011. Expenses have not grown with the revenue, it has high profit margins, and excellent management.

This stock is dramatically undervalued, currently selling at the bargain price of $1.26. One day this company is going to catch Wall Street's eye, and when that happens we'll see the share price go through the roof.

ctsolomonmd (< 20) Submitted: 2/13/2012 1:20:58 PM : Start Price: $9.17 OCLS Score: -80.83

totally under the radar. positive free cash flow per share. Huge market with disruptive technology. Medicare won't pay for wound infections and this company has a reasonable remedy. I own this stock.

HollowMountain (< 20) Submitted: 2/6/2011 2:12:45 PM : Start Price: $13.51 OCLS Score: -98.17

This company has had some problems in the past, but it sells a brand that is important in the healthcare field and is only going to expand in business as people look for cheaper alternatives to expensive prescription medications.

targetphil3 (< 20) Submitted: 10/14/2010 10:38:17 PM : Start Price: $12.25 OCLS Score: -109.33

wonder if new acne meds do good in mexico? I actually hope they market to military for wound treatments.

HGPD99 (< 20) Submitted: 9/20/2010 11:43:45 AM : Start Price: $10.64 OCLS Score: -109.23

Amazing new products in the medical field.

Hanks98 (< 20) Submitted: 8/6/2007 5:47:18 PM : Start Price: $67.41 OCLS Score: -114.76

Announcing their final FDA approval in September and the distribution deals will follow. This stock is a 10 bagger over the next year.